ArticleBMC pediatrics2025
Prevalence and perinatal risk factors of growth retardation in congenital diaphragmatic hernia survivors.
Article in BMC pediatrics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundGrowth retardation (GR) is one of the major morbidities in congenital diaphragmatic hernia (CDH). This study aimed to investigate the prevalence and perinatal risk factors of growth failure in CDH survivors.
methodsWe retrospectively reviewed the medical records of isolated CDH patients with gestational age ≥ 35 weeks who survived to 3 years of age. Weight and length(height) were measured at 1 year, 2 and 3 years of age. GR was defined when the Z-score of weight or height was below - 2.0. We analyzed and compared the prenatal and clinical characteristics, including anthropometric data, fetal lung volume measurement, and treatment modalities during initial hospitalization, between the GR group and the non-GR group.
resultsOf the 116 patients with isolated CDH, 86 patients survived to NICU discharge (74.1%). A total of 77 patients who survived 3 years of age with follow-up growth parameters available were included in the study analysis. The rates of GR at 1 year, 2 and 3 years of age was 15.6% (12/77), 14.3% (11/77), and 23.4% (18/77) respectively. Patients with GR at any of the three time points were classified into the GR group (20/77, 26%). Compared with the non-GR group, GR group had lower weight at birth. The incidence of systemic corticosteroid use, mostly with hydrocortisone, were greater in the GR group than the non-GR group. The parameters that indicate disease severity, including observed-expected lung-to-head ratio, liver herniation, inhaled nitric oxide use, ECMO, patch repair did not differ between the two groups. Multivariate analysis revealed that low birthweight and systemic corticosteroid use were associated with increased odds of GR. Cumulative corticosteroid exposure was associated with impaired height growth, particularly during the first two years.
conclusionFor the first 3 years of age, GR was observed a significant portion of CDH survivors. Early identification of high-risk patients and targeted interventions, including minimizing corticosteroid exposure and optimizing nutritional support, may improve growth outcomes in this vulnerable population.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.